



Apath, LLC HCV 3'NTR Infectious Clone Patent Estate Tangible Property and HCVcc Patent Estate Tangible Property

PLASMIDS

| HCV 3'NTR infectious clone plasmids | | Requires Sublicense to the WUSTL HCV 3'NTR Infectious Clones Patent Estate | | | |
|-------------------------------------|-----------------------------|---|-----------|-------------------|----------|
| APP | Name | HCV 3' NTR infectious clone (replicon) plasmid description | Available | Under Development | Proposed |
| 40 | J6/JFH1EMCVIREShRlucNeo | genotype 2a subgenomic replicon with Renilla luciferase reporter and NPTII selectable marker | X | | |
| 247 | Con/FL-Neo (I) | genotype 1b full-length replicon with NS5A (S2204I) adaptive mutation, NPTII selectable marker | X | | |
| 246 | Con1/FL (I) | genotype 1b full-length replicon with NS5A (S2204I) adaptive mutation | X | | |
| 237 | Con1/FL (I) pol | genotype 1b full-length replicon with NS5A (S2204I) adaptive mutation and GDD mutation in NS5B | X | | |
| 248 | Con1/FL | genotype 1b full-length replicon | X | | |
| 203 | Con1/SG-Neo (I) | genotype 1b subgenomic replicon with NS5A (S2204I) adaptive mutation and NPTII selectable marker | X | | |
| 221 | Con1/SG-Neo (I) pol | genotype 1b subgenomic replicon with NS5A (S2204I) adaptive mutation, NPTII selectable marker, and GDD mutation within NS5B | X | | |
| 277 | Con1/SG-Neo (AvaII) | genotype 1b subgenomic replicon with NPTII selectable marker and AvaII site | X | | |
| 270 | Con1/SG-Neo (AvaII) pol | genotype 1b subgenomic replicon with NPTII selectable marker, AvaII site, and GDD mutation in NS5B | X | | |
| 249 | Con1/SG-5'HE (I) | genotype 1b subgenomic replicon with NS5A (S2204I) adaptive mutation and chimeric IRES | X | | |
| 250 | Con1/SG-5'HE (I) pol | genotype 1b subgenomic replicon with NS5A (S2204I) adaptive mutation, chimeric IRES, and GDD | X | | |
| 252 | Con1/SG-Neo(delta 47) | genotype 1b subgenomic replicon with NS5A (S2204I) adaptive mutation, 47 amino acid deletion within NS5A, and NPTII selectable marker | X | | |
| 253 | Con1/SG-Neo(S2197P) | genotype 1b subgenomic replicon with NS5A (S2197P) adaptive mutation and NPTII selectable marker | X | | |
| 76 | Con1/SG-Neo(I)hRlucFMDV2aUb | genotype 1b subgenomic replicon with Renilla luciferase reporter, NPTII selectable marker, and NS5A (S2204I) adaptive mutation | X | | |
| 239 | H/FL-Neo (L+I) | genotype 1a full-length replicon with NS3 (P1496L) and NS5A (S2204I) adaptive mutations, NPTII selectable marker | X | | |
| 240 | H/FL (L+I) | genotype 1a full-length replicon with NS3 (P1496L) and NS5A (S2204I) adaptive mutations | X | | |
| 243 | H/FL | genotype 1a full-length replicon | X | | |
| 290 | H/FL pol | genotype 1a full-length replicon with GDD mutation in NS5B | X | | |
| 245 | H/SG-5'HE (L+I) | genotype 1a subgenomic replicon with NS3 (P1496L) and NS5A (S2204I) adaptive mutations and chimeric IRES | X | | |
| 251 | H/SG-5'HE (L+I) pol | genotype 1a subgenomic replicon with NS3 (P1496L) and NS5A (S2204I) adaptive mutations, chimeric IRES, and GDD mutation in NS5B | X | | |
| 238 | H/SG-Neo (L+I) | genotype 1a subgenomic replicon with NS3 (P1496L) and NS5A (S2204I) adaptive mutations and NPTII | X | | |
| 242 | H/SG-Neo (I) | genotype 1a subgenomic replicon with NS5A (S2204I) adaptive mutation and NPTII selectable marker | X | | |
| 241 | H/SG-Neo | genotype 1a subgenomic replicon with NPTII selectable marker | X | | |

| HCVcc Plasmids (for nomenclature overview, see schematic below) | | Requires Sublicense to the HCV 3'NTR Infectious Clones, PHS, The Rockefeller Univeristy and Toray Patent Estates | | | |
|---|--|--|-----------|-------------------|----------|
| APP | Name | HCVcc plasmid description | Available | Under Development | Proposed |
| 21 | J6/JFH (j6) cDNA | encodes a genotype 2a/2a chimeric HCV genome with NS2/NS3 chimeric junction | X | | |
| 23 | J6/JFH (j5.1) cDNA | encodes a genotype 2a/2a chimeric HCV genome with chimeric junction within NS2 | X | | |
| 36 | JFH cDNA | encodes a genotype 2a HCV genome (full-length JFH1 polyprotein) | X | | |
| 22 | mJ6/JFHRluc2 (j6) cDNA | encodes a genotype 2a/2a chimeric HCV genome containing Renilla luciferase reporter; monocistronic configuration; NS2/NS3 junction | X | | |
| 24 | mJ6/JFHRluc2 (j5.1) cDNA | encodes a genotype 2a/2a chimeric HCV genome containing Renilla luciferase reporter; monocistronic configuration; junction within NS2 | X | | |
| 55 | Con1/JFH (j5.1) cDNA | encodes a genotype 1b/2a chimeric HCV genome with chimeric junction within NS2 | X | | |
| 105 | Con1/JFH (j5.1; Y835C) cDNA | encodes a genotype 1b/2a chimeric HCV genome with chimeric junction within NS2; contains NS2 adaptive | X | | |
| 109 | biCon1/JFHRluc1 (j5.1) cDNA | encodes a genotype 1b/2a chimeric HCV genome containing humanized Renilla luciferase reporter; bicistronic configuration; junction within NS2 | X | | |
| 110 | mCon1/JFHRluc1 (j5.1) cDNA | encodes a genotype 1b/2a chimeric HCV genome containing humanized Renilla luciferase reporter; monocistronic configuration; junction within NS2 | X | | |
| 142 | Con1/JFH (j5.1; 8 adaptive muts) | encodes a genotype 1b/2a chimeric HCV genome with chimeric junction within NS2; contains eight | X | | |
| 143 | Con1/JFH (j5.1; adapted; 7 adapt muts) | encodes a genotype 1b/2a chimeric HCV genome with chimeric junction within NS2; contains seven | X | | |
| 144 | Con1/JFH (j5.1; adapted; 5 adapt muts (-E1E2)) | encodes a genotype 1b/2a chimeric HCV genome with chimeric junction within NS2; contains five adaptive mutations NOTE: lacks adaptive mutations in E1 and E2 | X | | |
| 146* | Con1/JFH (j5.1) (RU) | encodes a genotype 1b/2a chimeric HCV genome with chimeric junction within NS2 (produced at | | | X |
| 145* | H77/JFH (j6) (RU) | encodes a genotype 1a/2a chimeric HCV genome with NS2/NS3 chimeric junction (produced at Rockefeller | | | X |
| 53 | H77/JFH (j5.1) cDNA | encodes a genotype 1a/2a chimeric HCV genome with chimeric junction within NS2 | X | | |

| | | | | | |
|---|---|---|---|---|---|
| 99 | H77/JFH (j5.1; Y835H) cDNA | encodes a genotype 1a/2a chimeric HCV genome with chimeric junction within NS2; contains NS2 adaptive | X | | |
| 82 | mH77/JFHRluc1 (j5.1; Y835H) cDNA | encodes a genotype 1a/2a chimeric HCV genome containing humanized Renilla luciferase reporter; monocistronic configuration; junction within NS2; contains NS2 adaptive mutation | X | | |
| 104 | H77/JFH (j6; S1107T) cDNA | encodes a genotype 1a/2a chimeric HCV genome with NS2/NS3 junction; contains NS3 adaptive mutation | X | | |
| 108 | H77/JFH (j6; K12N, S1107T) cDNA | encodes a genotype 1a/2a chimeric HCV genome with NS2/NS3 junction; contains core, NS3 adaptive | X | | |
| 103 | H77/JFH (j6; I348S, S1107T) cDNA | encodes a genotype 1a/2a chimeric HCV genome with NS2/NS3 junction; contains E1, NS3 adaptive | X | | |
| 107 | H77/JFH (j6; K12N, I348S, S1107T) cDNA | encodes a genotype 1a/2a chimeric HCV genome with NS2/NS3 junction; contains core, E1, NS3 adaptive | X | | |
| 115 | biH77/JFHRluc1 (j6; K12N, S1107T) cDNA | encodes a genotype 1a/2a chimeric HCV genome containing humanized Renilla luciferase reporter; bicistronic configuration; NS2/NS3 junction; contains core, NS3 adaptive mutations | X | | |
| 116 | mH77/JFHRluc1 (j6; K12N, S1107T) cDNA | encodes a genotype 1a/2a chimeric HCV genome containing humanized Renilla luciferase reporter; monocistronic configuration; NS2/NS3 junction; contains core, NS3 adaptive mutation | X | | |
| 147* | J6/JFH (j6) (RU) | encodes a genotype 2a/2a chimeric HCV genome with NS2/NS3 junction | | | X |
| 148* | J6/JFH (j5.1) (RU) | encodes a genotype 2a/2a chimeric HCV genome with chimeric junction within NS2 | | | X |
| 149‡* | biGluc-Jc1 (RU) | encodes a genotype 2a/2a chimeric HCV genome containing humanized Gaussia luciferase reporter; bicistronic configuration; junction within NS2 | | | X |
| 150‡* | mJ6/JFHnsGluc2 (j5.1) (RU) | encodes a genotype 2a/2a chimeric HCV genome containing Gaussia luciferase reporter; monocistronic configuration; junction within NS2 | | | X |
| 151‡ | mCon1/JFHnsGluc2(j5.1; adapted; 5 adapt muts (-E1E2)) | encodes a genotype 1b/2a chimeric HCV genome containing humanized Gaussia luciferase; monocistronic configuration; junction within NS2; contains five adaptive mutations NOTE: lacks adaptive mutations in E1 | | X | |
| 152 | mCon1/JFHRluc2(j5.1; adapted; 5 adapt muts (-E1E2)) | encodes a genotype 1b/2a chimeric HCV genome containing Renilla luciferase; monocistronic configuration; junction within NS2; contains five adaptive mutations NOTE: lacks adaptive mutations in E1 | | X | |
| 159 | mCon1/JFHhRluc2(j5.1; adapted; 5 adapt muts (-E1E2)) | encodes a genotype 1b/2a chimeric HCV genome containing humanized Renilla luciferase; monocistronic configuration; junction within NS2; contains five adaptive mutations NOTE: lacks adaptive mutations in E1 | | X | |
| * RU indicates original constructs made by Rice Lab at The Rockefeller University | | | | | |
| ‡Contains Gaussia Luciferase | | | | | |

CELL LINES

| HCV 3' NTR infectious clone (replicon) cell lines | | Requires Sublicense to the WUSTL HCV 3'NTR Infectious Clones Patent Estate | | | |
|--|---|---|-----------|-------------------|----------|
| APC | Name | HCV 3' NTR infectious clone (replicon) cell line description | Available | Under Development | Proposed |
| 136 | J6/JFH1EMCVIREShRlucNeo | genotype 2a subgenomic replicon with Renilla luciferase reporter and NPTII selectable marker | | X | |
| 5 | Clone A | genotype 1b subgenomic replicon with NS3 (Q1112R) and NS5A (S2204I) adaptive mutations and NPTII selectable marker | X | | |
| 40 | Con1/SG-Neo (I) (Clone B) | genotype 1b subgenomic replicon with NS5A (S2204I) adaptive mutation and NPTII selectable marker | X | | |
| 4 | Con1/SG-Neo(delta 47) (Ava.1) | genotype 1b subgenomic replicon with NS5A (S2204I) adaptive mutation, 47 amino acid deletion within NS5A, and NPTII selectable marker | X | | |
| 3 | Ava.5 | genotype 1b subgenomic replicon with NS3 (K1609E), NS4B (I950G), NS5A (R2189G) adaptive mutations and NPTII selectable marker | X | | |
| 41 | Con1/SG-Neo(S2197P) (Huh.2) | genotype 1b subgenomic replicon with NS5A (S2197P) adaptive mutation and NPTII selectable marker | X | | |
| 20 | Con1/SG-Neo (Huh.8) | genotype 1b subgenomic replicon with NPTII selectable marker | X | | |
| 144 | Con1/SG-Neo(DjhRlucFMDV2aUb | genotype 1b subgenomic replicon with Renilla luciferase reporter, NPTII selectable marker, and NS5A (S2204I) adaptive mutation | | X | |
| 140 | J6/JFH1EMCVIREShRlucNeo (in Huh7.5 cells) | genotype 2a subgenomic replicon with Renilla luciferase reporter and NPTII selectable marker | | X | |
| 143 | Con1/SG-Neo(DjhRluc2aUb (in Huh7.5 cells) | genotype 1b subgenomic replicon with Renilla luciferase reporter, NPTII selectable marker, and NS5A (S2204I) adaptive mutation | | X | |
| 50* | Con1/FL-Neo (I) (in Huh7.5 cells) | genotype 1b full-length replicon with NS5A (S2204I) adaptive mutation and NPTII selectable marker | X | | |
| 55* | Con1/SG-Neo (I) (in Huh7.5 cells) | genotype 1b subgenomic replicon with NS5A (S2204I) adaptive mutation and NPTII selectable marker | X | | |
| 89* | H/SG-Neo(L+I) (in Huh7.5 cells) | genotype 1a subgenomic replicon with NS3 (P1496L) and NS5A (S2204I) adaptive mutations and NPTII selectable marker | X | | |
| 103* | H/FL-Neo(L+I) (in Huh7.5 cells) | genotype 1a full-length replicon with NS3 (P1496L) and NS5A (S2204I) adaptive mutations and NPTII selectable marker | X | | |
| * Requires Sublicense to the WUSTL Highly Permissive Cell Line Patent Estate | | | | | |
| Highly Permissive Cell Lines | | Requires Sublicense to the WUSTL Highly Permissive Cell Line Patent Estate | | | |
| APC | Name | Cell line description | Available | Under Development | Proposed |
| 49 | Huh-7.5 cells | cell line that is highly permissive to HCV replication; derived by "curing" replicon cell line via Interferon treatment | X | | |

| | | | | | |
|--|-------------------|---|---|--|--|
| 167* | Huh-7.5.1 | cell that that was generated by "curing" replicon-containing Huh7.5 cells | X | | |
| 170* | Huh-7.5.1 clone 2 | cell that that was generated by "curing" replicon-containing Huh7.5.1 cells | X | | |
| * Purchase of APC 49 is required with APC 167 or APC 170 | | | | | |

VIRUSES --includes 660,000 TCID50 units (sufficient for screening three 96-well plates at MOI=0.1)

| Non-reporter viruses | | Requires Sublicense to the HCV 3'NTR Infectious Clones, PHS/NIH, Rockefeller University and Toray Patent Estates | | | |
|----------------------|--|---|-----------|-------------------|----------|
| APV | Name | HCVcc virus description | Available | Under Development | Proposed |
| 21 | J6/JFH (j6) | genotype 2a/2a chimeric HCV genome with NS2/NS3 chimeric junction | X | | |
| 23 | J6/JFH (j5.1) | genotype 2a/2a chimeric HCV genome with chimeric junction within NS2 | X | | |
| 36 | JFH cDNA | genotype 2a HCV genome (full-length JFH1 polyprotein) | | | X |
| 147* | J6/JFH (j6) (RU) | genotype 2a/2a chimeric HCV genome with NS2/NS3 junction | | | X |
| 148* | J6/JFH (j5.1) (RU) | genotype 2a/2a chimeric HCV genome with chimeric junction within NS2 | | | X |
| 55 | Con1/JFH (j5.1) | genotype 1b/2a chimeric HCV genome with chimeric junction within NS2 | | | X |
| 142 | Con1/JFH (j5.1; 8 adaptive muts) | genotype 1b/2a chimeric HCV genome with chimeric junction within NS2; contains eight adaptive | | | X |
| 143 | Con1/JFH (j5.1; adapted; 7 adapt muts) | genotype 1b/2a chimeric HCV genome with chimeric junction within NS2; contains seven adaptive mutations | | | X |
| 144 | Con1/JFH (j5.1; adapted; 5 adapt muts (-E1E2)) | genotype 1b/2a chimeric HCV genome with chimeric junction within NS2; contains five adaptive mutations NOTE: lacks adaptive mutations in E1 and E2 | X | | |
| 146* | Con1/JFH (j5.1) (RU) | genotype 1b/2a chimeric HCV genome with chimeric junction within NS2 (produced at Rockefeller | | | X |
| 145* | H77/JFH (j6) (RU) | genotype 1a/2a chimeric HCV genome with NS2/NS3 chimeric junction (produced at Rockefeller | | | X |
| 99 | H77/JFH (j5.1; Y835H) | genotype 1a/2a chimeric HCV genome with chimeric junction within NS2; contains NS2 adaptive mutation | | | X |
| 104 | H77/JFH (j6; S1107T) | genotype 1a/2a chimeric HCV genome with NS2/NS3 junction; contains NS3 adaptive mutation | | X | |
| 108 | H77/JFH (j6; K12N, S1107T) | genotype 1a/2a chimeric HCV genome with NS2/NS3 junction; contains core, NS3 adaptive mutations | | | X |
| 103 | H77/JFH (j6; I348S, S1107T) | genotype 1a/2a chimeric HCV genome with NS2/NS3 junction; contains E1, NS3 adaptive mutations | | | X |
| 107 | H77/JFH (j6; K12N, I348S, S1107T) | genotype 1a/2a chimeric HCV genome with NS2/NS3 junction; contains core, E1, NS3 adaptive mutations | | | X |

* RU indicates original constructs made by Rice Lab at The Rockefeller University

| Reporter viruses | | Requires Sublicense to the HCV 3'NTR Infectious Clones, PHS/NIH, The Rockefeller University and Toray Patent Estate | | | |
|------------------|---|--|-----------|-------------------|----------|
| APV | Name | HCVcc virus description | Available | Under Development | Proposed |
| 22 | mJ6/JFHRluc2 (j6) | genotype 2a/2a chimeric HCV genome containing Renilla luciferase reporter; monocistronic configuration; NS2/NS3 junction | | | X |
| 24 | mJ6/JFHRluc2 (j5.1) | genotype 2a/2a chimeric HCV genome containing Renilla luciferase reporter; monocistronic configuration; junction within NS2 | X | | |
| 149*‡ | biGluc-Jc1 (RU) | genotype 2a/2a chimeric HCV genome containing humanized Gaussia luciferase reporter; bicistronic configuration; junction within NS2 | | | X |
| 150*‡ | mJ6/JFHnsGluc2 (j5.1) (RU) | genotype 2a/2a chimeric HCV genome containing Gaussia luciferase reporter; monocistronic configuration; junction within NS2 | | X | |
| 109 | biCon1/JFHRluc1 (j5.1) | genotype 1b/2a chimeric HCV genome containing humanized Renilla luciferase reporter; bicistronic configuration; junction within NS2 | | | X |
| 110 | mCon1/JFHRluc1 (j5.1) | genotype 1b/2a chimeric HCV genome containing humanized Renilla luciferase reporter; monocistronic configuration; junction within NS2 | | | X |
| 151‡ | mCon1/JFHnsGluc2(j5.1; adapted; 5 adapt muts (-E1E2)) | genotype 1b/2a chimeric HCV genome containing humanized Gaussia luciferase; monocistronic configuration; junction within NS2; contains five adaptive mutations NOTE: lacks adaptive mutations in | | X | |
| 152 | mCon1/JFHRluc2(j5.1; adapted; 5 adapt muts (-E1E2)) | genotype 1b/2a chimeric HCV genome containing Renilla luciferase; monocistronic configuration; junction within NS2; contains five adaptive mutations NOTE: lacks adaptive mutations in E1 and E2 | | X | |
| 159 | mCon1/JFHhRluc2(j5.1; adapted; 5 adapt muts (-E1E2)) | genotype 1b/2a chimeric HCV genome containing humanized Renilla luciferase; monocistronic configuration; junction within NS2; contains five adaptive mutations NOTE: lacks adaptive mutations in | | X | |
| 82 | mH77/JFHRluc1 (j5.1; Y835H) | genotype 1a/2a chimeric HCV genome containing humanized Renilla luciferase reporter; monocistronic configuration; junction within NS2; contains NS2 adaptive mutation | | | X |
| 115 | biH77/JFHRluc1 (j6; K12N, S1107T) | genotype 1a/2a chimeric HCV genome containing humanized Renilla luciferase reporter; bicistronic configuration; NS2/NS3 junction; contains core, NS3 adaptive mutations | | | X |
| 116 | mH77/JFHRluc1 (j6; K12N, S1107T) | genotype 1a/2a chimeric HCV genome containing humanized Renilla luciferase reporter; monocistronic configuration; NS2/NS3 junction; contains core, NS3 adaptive mutation | | | X |

* RU indicates original constructs made by Rice Lab at The Rockefeller University

‡Contains Gaussia Luciferase

| APV | Name | HCVcc virus description | Available | Under Development | Proposed |
|-------|---|--|-----------|-------------------|----------|
| 24 | mJ6/JFHRluc2 (j5.1) | genotype 2a/2a chimeric HCV genome containing Renilla luciferase reporter; monocistronic configuration; junction within NS2 | X | | |
| 23 | J6/JFH(j5.1) | genotype 2a/2a chimeric HCV genome with chimeric junction within NS2 | X | | |
| 21 | J6/JFH1(j6) | genotype 2a/2a chimeric HCV genome with NS2/NS3 chimeric junction | X | | |
| 104 | H77/JFH (j6; S1107T) | genotype 1a/2a chimeric HCV genome with NS2/NS3 junction; contains NS3 adaptive mutation | | X | |
| 174‡ | H77/JFHnsGluc2 (j6; S1107T) | genotype 1a/2a chimeric HCV genome containing humanized Gaussia luciferase reporter; monocistronic configuration; NS2/NS3 junction | | X | |
| 144 | Con1/JFH (j5.1; adapted; 5 adapt muts (-E1E2)) | genotype 2a/2a chimeric HCV genome with chimeric junction within NS2; contains five adaptive mutations NOTE: lacks adaptive mutations in E1 and E2 | X | | |
| 150*‡ | mJ6/JFHnsGluc2 (j5.1) (RU) | genotype 2a/2a chimeric HCV genome containing Gaussia luciferase reporter; monocistronic configuration; junction within NS2 | X | | |
| 151‡ | mCon1/JFHnsGluc2(j5.1; adapted; 5 adapt muts (-E1E2)) | genotype 1b/2a chimeric HCV genome containing humanized Gaussia luciferase; monocistronic configuration; junction within NS2; contains five adaptive mutations NOTE: lacks adaptive mutations in | X | | |
| 152** | mCon1/JFHRluc2(j5.1; adapted; 5 adapt muts (-E1E2)) | genotype 1b/2a chimeric HCV genome containing Renilla luciferase; monocistronic configuration; junction within NS2; contains five adaptive mutations NOTE: lacks adaptive mutations in E1 and E2 | X | | |


* RU indicates original constructs from Rice Lab at The Rockefeller University

‡Contains Gaussia Luciferase

** Viral System Defined Below

NOMENCLATURE FOR NON-REPORTER CONSTRUCTS

- Nomenclature for non-reporter constructs:
 - strain/strain (chimeric junction, adaptive mutations)
 - e. g. for APP104: H77/JFH(j6; S1107T)
- Nomenclature for reporter constructs:
 - Mono- vs bicistronic, strain/strain, reporter location (chimeric junction, adaptive mutations)
 - e. g. for APP24: mJ6/JFHRluc2(j5.1)



Contents for GT1b/2a Renilla Luciferase HCV Infection System APV152 (Utilized as an example for all HCV Infection Systems)

| Materials Included In Viral Infection System: | |
|---|---|
| Reagents: | <ul style="list-style-type: none"> * 100 ml fetal bovine serum (Atlanta Biologicals lot# L0097) * 2 tubes of 1 ug plasmid aliquots (blue-capped tubes) * 2 tubes of 5 ul aliquots of 10 mM HCV polymerase inhibitor (Pol. Inhib.) (in DMSO) (green-capped tubes) * 2 tubes of 5 ul aliquots of 10 mM HCV cell-based inhibitor (Cell. Inhib.) (in DMSO) (red-capped tubes) |

- * 6 vials Huh7.5 cells, each at 2.5×10^6 cells/vial
- * 6 vials of virus, each containing 110,000 TCID₅₀ units/vial (enough for 48 well experiment at MOI = 0.1)
- * aNS5A mAb (9E10) (APA1), 10 ul aliquot (*yellow-capped tubes*)

Documents Included In Viral Infection System:

QC analysis sheets:

- * Quality control analysis of companion vial of Huh7.5 cells (APC49)
- * Quality control analysis of companion vial of APV152

Plasmid information:

- * Graphic map
- * Features
- * Sequence

Protocols:

- * Culturing and Maintenance of Huh7.5 cells (APC49)
- * Transformation, purification, and verification of APP152 plasmid
- * Production of APV152 via electroporation
- * Concentration of APV152 via Ultrafiltration
- * Titering APV152 by limiting dilution assay
- * EC50 Determination of HCV Inhibitors in APV152 Infection Assay; Cellular target, HCV polymerase target
- * Recommended experiments to evaluate serum lots for HCVcc production

Response of APV152 to Positive Controls

